1107 related articles for article (PubMed ID: 32609313)
1. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
2. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
[TBL] [Abstract][Full Text] [Related]
6. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
7. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
[TBL] [Abstract][Full Text] [Related]
8. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
[TBL] [Abstract][Full Text] [Related]
11. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
12. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
Ballantyne CM; Bays HE; Louie MJ; Smart J; Zhang Y; Ray KK
J Am Heart Assoc; 2022 Aug; 11(15):e024531. PubMed ID: 35916348
[TBL] [Abstract][Full Text] [Related]
16. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
[TBL] [Abstract][Full Text] [Related]
17. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Rubino J; MacDougall DE; Sterling LR; Hanselman JC; Nicholls SJ
Atherosclerosis; 2021 Mar; 320():122-128. PubMed ID: 33514449
[TBL] [Abstract][Full Text] [Related]
18. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
19. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
